Ashvattha Therapeutics Presented Promising Preclinical Data on Novel Macrophage Switching Nanomedicine D-4559 at AACR Annual Meeting

Data demonstrated D-4559 switches tumor associated macrophages from an M2 to M1 pro-inflammatory phenotype leading to reduction in tumor growth in a mouse model of hepatocellular carcinoma The data supports development of the potent macrophage switching drug as a potentially safe and effective agent that can be used systemically for the treatment of hepatocellular carcinoma … Read more

Ashvattha Therapeutics to Present Preclinical Data at the AACR and ARVO 2023 Annual Meetings

Preclinical data to be presented at AACR will showcase the potential effect of D-4559, a potent macrophage switching nanomedicine, on reducing tumor growth in a mouse model of hepatocellular carcinoma, a type of liver cancer Ashvattha will present preclinical data at ARVO on its oral formulation of D-4517.2, a potent anti-angiogenic nanomedicine, in a laser-induced … Read more

Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 1 Study of [18F]OP-801 for Use as Imaging Agent

– The study will evaluate the safety, tolerability and ability of [18F]OP-801 to cross the blood brain barrier and selectively target neuroinflammation in individuals with ALS and healthy volunteers–   REDWOOD CITY, Calif., February 6, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel nanomedicines called hydroxyl dendrimer therapeutics (HDT), today announced that the … Read more

Ashvattha Therapeutics to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif., February 2, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class of precision medicines, today announced that the Company will provide a corporate overview at two upcoming investor conferences. The corporate overview will highlight the company’s innovative approach to precision nanomedicine … Read more

Ashvattha Therapeutics to Present at Biotech Showcase 2023

REDWOOD CITY, Calif., January 3, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class of precision medicines, today announced that the Company will provide a corporate overview at Biotech Showcase 2023 taking place in San Francisco, California, from January 9-11, 2023. Presenter Jeffrey Cleland, … Read more

Ashvattha Therapeutics Announces the Appointment of Steve Maricich, M.D., Ph.D. as Chief Medical Officer

REDWOOD CITY, Calif., October 20, 2022 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics (HDTs), today announced that Steve Maricich, M.D., Ph.D., joined the company as chief medical officer. Dr. Maricich joins Ashvattha as a seasoned clinical development physician and translational scientist with more than 15 years of industry and academic … Read more

Ashvattha Therapeutics Announces Preclinical Data on Hydroxyl Dendrimer Based PET Tracer [18F]OP-801 Presented at the 2022 World Molecular Imaging Congress

– Data demonstrated [18F]OP-801 is a promising tracer for imaging activated macrophages/microglia with high sensitivity in the lumbar spine of a murine model of multiple sclerosis (MS) – – Treatment of MS model mice with a hydroxyl dendrimer CSF1R inhibitor demonstrated selective killing of reactive microglia and lower uptake of the investigative PET tracer compared … Read more

Ashvattha Therapeutics Announces Presentations of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 World Molecular Imaging Congress (WMIC)

– Scientific collaborators at Stanford University will present data on an imaging and treatment regimen demonstrating the microglial targeting of [18F]OP-801 in a mouse model of multiple sclerosis and the synthesis of [18F]OP-801 for the ongoing clinical trial –   REDWOOD CITY, Calif., September 15, 2022 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel … Read more

Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 2 Study of D-4517.2 for the Treatment of Wet AMD and DME

– First patient was enrolled as part of a two-stage Phase 2 study evaluating Ashvattha’s subcutaneous (SC) anti-VEGF wet AMD and DME candidate, D-4517.2 –   – The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously (SC) administered D-4517.2 compared to intravitreal (IVT) injection of aflibercept, … Read more

Ashvattha Therapeutics Announces Preclinical Data at the 2022 Alzheimer’s Association International Conference (AAIC) Demonstrating its Hydroxyl Dendrimer-Based Imaging Agent [18F]OP-801 Can Detect Early-Stage Neuroinflammation with a Higher Sensitivity Than TSPO-PET

– Data highlights [18F]OP-801’s differentiated imaging profile as a promising tracer for visualizing the progression of neuroinflammation – REDWOOD CITY, Calif., August 1, 2022 – Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801, can detect … Read more